HempLife Today to begin Trial Offer of its popular CannazALL CBD GelCaps as completed BETA testing indicates this offer will add 25,000 to 50,000 new customers in the next 12 to14 months

DENVER, CO - (NewMediaWire) - November 01, 2016 - CEO of Ubiquitech Software Corp. (OTC PINK: UBQU), with pending symbol and name change to HempLife Today™, and the management of HempLife Today™ are announcing that it has completed a very successful BETA test of the previously announced (9.16.2016) Trial Offer of its popular CannazALL™ CBD GelCaps and will now start this campaign to the general public. This Trial Offer will differ slightly from the originally announced offer and cost just $9.95 for shipping and processing. 

Through successful BETA testing the Company proved that it can access more of the free traffic that is already coming to the various Websites and Landing Pages the company operates. Company data show that 20% - 40% of the existing traffic will take advantage of this offer creating 25,000 - 50,000 new customers to the CannazALL™ CBD brand by giving them the CBD experience that converts them to becoming long term consumers.

This offer will consist of (6) 25mg CannazALL™ CBD GelCaps along with a complete introduction to the company and instructions on how to best benefit and have the best CBD experience possible. The consumer will also receive an insert on other CannazALL™ products as well as a 30% off coupon. The consumer will receive all of this for a one-time cost of just $9.95 shipping and processing.

Because this Trial is offered to the existing traffic to the Company's Websites and Landing Pages there are no additional advertising costs to the Company. In addition, the shipping and processing cost augments any expenses to the company and results in a 100% net gain per new customer converted.

The Company data shows that charging a nominal amount ($9.95), will create a better, more committed, customer to the CannazALL™ brand, but still result in the large percentage of new customers taking advantage of this generous offer.

"With this offer we can get a sample of our product into the hands of thousands of people monthly," said James Ballas, CEO. "And once people experience our products our reorder rate is incredible. This will add millions to our bottom line sales without incurrent a penny in additional costs. We are very fortunate to be in this position but that is the power of our quality brand."

The Company bases its projections on the percentage of customers who were converted by the Trial Offer during the BETA test period and believes this will add 25,000 - 50,000 new customers over the next 12-14 months, at zero advertising costs.

The company expects to have this offer on the "CBD Pricing" page @ www.HempLifeToday.com as well as its various Landing Pages, Social Media, and Content blogs by Wednesday, November 9th.

About Ubiquitech (HempLife Today™)

Ubiquitech Software Corp, through its subsidiaries is a dynamic multi-media, multi-faceted corporation utilizing state-of-the-art global internet marketing, Direct Response (DRTV) Television, Radio, and traditional marketing, to drive traffic to the new and emerging multi-billion dollar industries like its subsidiary HempLifeToday.com™

HempLifeToday™ focuses on the exciting and dynamic new thinking in the world today that recognizes the important health and life enriching enhancement that CBD Oil from the Hemp plant can bring. Through its network of quality USA growers HempLifeToday.com™ has developed multiple and proprietary CannazALL™ CBD oil products that include; It's popular CBD Tinctures, Oils, GelCaps, CBD Powder, Skin Salve, Wax Crumble, and e-liquid, all offered @ www.HempLifeToday.com

This press release contains forward-looking statements. Words such as "expects", "intends'', "believes'', and similar expressions reflecting something other than historical fact are intended to identify forward-looking statements, but are not the exclusive means of identifying such statements. These forward-looking statements involve a number of risks and uncertainties, including the timely development and market acceptance of products and technologies, the ability to secure additional sources of finance, the ability to reduce operating expenses, and other factors described in the Company's filings with the OTC Markets Group. The actual results that the Company achieves may differ materially from any forward-looking statement due to such risks and uncertainties. The Company undertakes no obligation to revise or update any forward- looking statements in order to reflect events or circumstances that may arise after the date of this release.